The predictors of outcome in immunocompetent patients with hematogenous candidasis

International Journal of Infectious Diseases

Volumn 8, Issue 3, 2004, Pages 180-186

  Safdar, Amar ^a,b   Bannister, Thomas W ^a   Safdar, Zeenat ^c  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Fungemia; Immunocompetent host; Immunosuppressed host; Ischemic heart disease; Non albicans candidemia; Predictors of outcome

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; MACROLIDE; MONOBACTAM DERIVATIVE; NYSTATIN; PENICILLIN G; PHENYLBUTAZONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TRIAZOLE DERIVATIVE;

ABDOMINAL SURGERY; ADOLESCENT; ADULT; AGE; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD FLOW; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDIASIS; CHILD; COMORBIDITY; DEATH; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FUNGAL STRAIN; FUNGEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INFANT; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPENIA; NEWBORN; NONHUMAN; PELVIS SURGERY; PREDICTION; PREMATURITY; PROGNOSIS; RETROSPECTIVE STUDY; SPECIES; SURVIVAL; TREATMENT OUTCOME;

EID: 2442434578     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2003.05.003     Document Type: Article

References (29)

1. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
2. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001;17:531-70.
3. Blumberg HM, Jarvis WR, Edwards JE, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS Prospective Multicenter Study. Clin Infect Dis 2002;33:177-86.
4. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999;29:1164-70.
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RR Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
6. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States. 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
7. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence based review. Clin Infect Dis 2002;34:591-9.
8. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600-2.
9. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
10. Anaissie EJ, Rex JH, Uzun H, Vartivarian S. Predictors of outcome in cancer patients with candidemia. Am J Med 1998;104:238-45.
11. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001;32:1713-7.
12. Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center - In vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309-21.
13. Safdar A, van Rhee F, Henslee-Downey JP, Singal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001;28:873-8.
14. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RR Secular trends of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
15. Yazdanparast K, Auger P, Marchand R, Carrier M, Cartier R. Predictive value of Candida colonization index in 131 patients undergoing two different cardiovascular surgical procedures. J Cardiovasc Surg (Torino) 2001;42:339-43.
16. Safdar A, Armstrong D. Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. Bone Marrow Transplant 2002;30:931-5.
17. Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001;45:2129-33.
18. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747-51.
19. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
20. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
21. Diekema DL, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.
22. Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000;46:1001-8.
23. Gumbo T, Isada CM, Hall G, Karafa MT, Gordon SM. Candida glabrata fungemia. Clinical features of 139 patients. Medicine 1996;78:220-7.
24. Safdar A, Cross EW, Chaturvedi V, Perlin DS, Armstrong D. Prolonged candidemia in patients with cancer. Clin Infect Dis 2002;35:778-9.
25. Kovacicova G, Lovaszova M, Hanzen J, et al. Persistent fungemia - risk factors and outcome in 40 episodes. J Chemother 2001;13:429-33.
26. Fidel Jr PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96.
27. Blot S, Vandewoude K, Hoste E, Poelaert J, Colardyn F. Outcome in critically ill patients with candidal fungemia: Candida albicans vs. Candida glabrata. J Hosp Infect 2001;47:308-13.
28. Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002;44:11-6.
29. Brieland J, Essig D, Jackson C, et al. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompromised mice. Infect Immun 2001;69:5046-55.